Key result
An admission neutrophil count ≥7,260 cells/mm³ was an independent predictor of long-term adverse cardiac events (OR 3.8, p=0.002) in patients treated with primary angioplasty for acute myocardial infarction.
Why the study?
Does a high admission neutrophil count predict long-term adverse cardiac events in patients treated with primary angioplasty for anterior wall acute myocardial infarction?
Population
228 consecutive patients with a first anterior wall acute myocardial infarction who underwent primary…
Comparison
High admission neutrophil count (≥7,260 cells/mm³) vs Low admission neutrophil count (<7,260 cells/mm³)
Design
Cohort
Follow-up
average 52±28 months
Authors
Loading...
May aid risk stratification post-primary PCI; leaves open whether neutrophil-targeted therapies alter long-term outcomes.
Cohort (n=228)
No
Does a high admission neutrophil count predict long-term adverse cardiac events in patients treated with primary angioplasty for anterior wall acute myocardial infarction?
Odds Ratio: 3.8
Absolute Event Rate: 28% vs 9%
p-value: p=0.002
An elevated admission neutrophil count (≥7,260 cells/mm³) is a simple, noninvasive marker that independently predicts impaired microvascular perfusion, left ventricular dilation, and long-term adverse cardiac events in patients undergoing primary angioplasty for anterior AMI.
Takahashi et al. (2008) conducted a cohort in Acute Myocardial Infarction (n=228). Admission neutrophil count ≥7,260 cells/mm³ vs. Admission neutrophil count <7,260 cells/mm³ was evaluated on Long-term adverse cardiac events (cardiac death, recurrent AMI, and CHF requiring hospitalization) (OR 3.8, p=0.002). An admission neutrophil count ≥7,260 cells/mm³ was an independent predictor of long-term adverse cardiac events (OR 3.8, p=0.002) in patients treated with primary angioplasty for acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: